MARKET

ORXOF

ORXOF

Orexo Ab
OTCQX
2.900
NaN%
Closed 09:30 02/06 EST
OPEN
--
PREV CLOSE
2.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
2.550
MARKET CAP
--
P/E (TTM)
-4.6721
1D
5D
1M
3M
1Y
5Y
1D
Orexo AB posts Q4 2025 net earnings of SEK 724.8 million after Zubsolv divestment
Reuters · 3d ago
Orexo AB erzielt im vierten Quartal 2025 einen Nettoertrag aus fortgeführten Aktivitäten von -115,6 Mio. SEK, was einer Verbesserung um 35 Prozent entspricht
Reuters · 3d ago
Orexo to Present New Strategy and AmorphOX Pipeline at March R&D Day
TipRanks · 4d ago
Orexo to Present 2025 Full-Year Results with Focus on Zubsolv US Divestment
TipRanks · 01/23 10:03
Orexo Completes Zubsolv US Rights Deal With Dexcel to Refocus on AmorphOX Pipeline
TipRanks · 12/31/2025 16:33
Orexo Sells US Rights to Zubsolv to Dexcel to Repay Debt and Fund AmorphOX Pipeline
TipRanks · 12/22/2025 20:33
Orexo Sells Zubsolv US Business to Dexcel Pharma USA
Reuters · 12/22/2025 20:02
Orexo AB Secures BARDA Partnership for Development of OX390 Overdose Rescue Therapy
Reuters · 12/05/2025 08:00
More
About ORXOF
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB stock information, including OTCQX: ORXOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOF stock methods without spending real money on the virtual paper trading platform.